Value of plasma free DNA in the diagnosis of non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2017.06.011

Abstract

Abstract:

Objective

To evaluate the value of plasma free DNA in the diagnosis of non-small cell lung cancer (NSCLC).

Methods

Plasma was collected from 116 patients with non-small cell lung cancer admitted to respiratory department, and 120 healthy subjects from Medical examination center, Shanxi Provincial People′s Hospital. Plasma free DNA was extracted and detected by fluorescence quantitative polymerase chain reaction, PCR.

Results

The plasma free DNA level of healthy people was (18.65±6.30) ng/ml, and the plasma free DNA level in patients with non-small cell lung cancer was (200.70±88.54) ng/ml, the difference was statistically significant(P<0.01). The plasma free DNA content of stage Ⅰ/Ⅱ non-small cell lung cancer was (172.75±72.87) ng/ml, and the plasma circulating DNA content in stage Ⅲ/Ⅳ non-small cell lung cancer was (221.88±93.86) ng/ml, (P<0.05). There was no significant correlation between sex, age, smoking status and histological type (P>0.05).

Conclusion

Plasma circulating DNA is a potentially valuable biomarker that may be an effective tool for early diagnosis and clinical staging of non-small cell lung cancer.

Key words: Non-small cell lung cancer, Plasma free DNA, Early diagnosis, Tumor marker

Jie Du, Yongjie Sui, Hongyan Li, Shuili Wang. Value of plasma free DNA in the diagnosis of non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 686-689.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.06.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I06/686

Figures/Tables 2

References 20

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]．中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
2	Maione P, Rossi A, Sacco PC, et al. Advance in chemotherapy in advanced non-small-cell Lung cancer[J]. Expert Opin Pharmacother, 2010, 11(18):2997-3007.
3	Diaz LA Jr, Bardelli A. Liquid Biopsies: Genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6):579-586.
4	Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls[J]. J Mol Diagn, 2009, 11(3):182-185.
5	Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer[J]. Int J Cancer, 2013, 133(2):346-356.
6	Nakao M, Muramatsu H, Sone K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: a retrospective analysis[J]. Mol Clin Oncol, 2015, 3(2):403-407.
7	Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients[J]. Anti-cancer Drngs, 2002, 13(4):353-357.
8	Lee HS, Hwang SM, Kim TS, et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon[J]. Transl Oncol, 2013, 6(3):290-296.
9	Wu Y, Du X, Xue C, et al. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer[J]. Med Oncol, 2013, 30(4):737.
10	Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5):552-558.
11	Ulivi P, Mercatali L, Casoni GL, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis[J]. PLoS One, 2013, 8(2):e57401.
12	Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types[J]. Mol Oncol, 2015, 9(4):783-790.
13	Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease[J]. Br J Cancer, 2015, 113(3):476-483.
14	邓水秋，欧阳学农，余宗阳，等. 晚期非小细胞肺癌血清游离DNA水平变化及意义[J]. 山东医药，2013, 53(30):6-8.
15	Madhavan D, Wallwiener M, Bents, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat, 2014, 146(1):163-174.
16	Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancerdetection[J]. Tumori, 2014, 100(2):115-121.
17	Battaglia P, Baritono E, Remo A, et al. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer[J]. Tumori, 2014, 100(2):122-127.
18	Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 16(8):937-948.
19	Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma[J]. Int J Cancer, 2014, 135(9):2215-2222.
20	Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015，16(8):937-948.

临床资料		例数	游离DNA水平	t值	P值
性别		?	?	1.9845	0.7602
?	男	64	198.38±80.98	?	?
?	女	52	203.56±97.78	?	?
年龄/岁		?	?	?	?
?	≤60	49	194.32±87.52	1.9830	0.5076
?	>60	67	205.37±89.64	?	?
吸烟		?	?	?	?
?	有	68	206.06±93.10	1.9822	0.4303
?	无	48	193.11±82.01	?	?
病理类型		?	?	?	?
?	腺癌	60	207.90±80.58	1.9824	0.3698
?	鳞癌	56	192.98±96.48	?	?
临床分期		?	?	?	?
?	Ⅰ/Ⅱ期	50	172.75±72.87	1.9812	0.0019
?	Ⅲ/Ⅳ期	66	221.88±93.86	?	?

临床资料		例数	游离DNA水平	t值	P值
性别		?	?	1.9845	0.7602
?	男	64	198.38±80.98	?	?
?	女	52	203.56±97.78	?	?
年龄/岁		?	?	?	?
?	≤60	49	194.32±87.52	1.9830	0.5076
?	>60	67	205.37±89.64	?	?
吸烟		?	?	?	?
?	有	68	206.06±93.10	1.9822	0.4303
?	无	48	193.11±82.01	?	?
病理类型		?	?	?	?
?	腺癌	60	207.90±80.58	1.9824	0.3698
?	鳞癌	56	192.98±96.48	?	?
临床分期		?	?	?	?
?	Ⅰ/Ⅱ期	50	172.75±72.87	1.9812	0.0019
?	Ⅲ/Ⅳ期	66	221.88±93.86	?	?

[1]	Chunnuo He, Zhimin Tian, Huanxi Li, Haoyue Wu, Kaipeng Zhuang, Shenghu Zhou, Haoqiang Zhang. Research progress in diagnosis and treatment of pediatric developmental hip dysplasia [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(04): 497-504.
[2]	Linjuan Zhao, Jie Lv, Wensheng Wang, Demao Ma, Tao Hou. Study on the effect of ultrasound guided resection of stellate and cylindrical lactation preserving areas with staining marks [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 634-637.
[3]	Yanbin Du, Tao Huang, Tiankuo Kou, Ying Shi. Application effect of double mirror combined radical operation and laparoscopic radical operation in patients with early colon cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(03): 275-278.
[4]	Wenxin Xie, Le Ma, Ye Liu, Xiaoming Cao, Wanchun Zhang. The application value of prostate specific membrane antigen PET/CT in the diagnosis and treatment of renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 514-519.
[5]	Jing Zhao, Ye Fan, Yating You, Hui Chen, Jing Wang, Jing Zhang. Diagnostic value of ultrasound image features combined with virtual bronchoscopic navigation and radial endobronchial ultrasound in peripheral lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 524-528.
[6]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[7]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[8]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[9]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[10]	Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.
[11]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[12]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[13]	Chuan Ouyang-, Qiaozhen Zhu, Lin Ouyang-. Research progress on biometabolic characteristics and evaluation techniques for intervertebral disc degeneration [J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(03): 206-211.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.

Please choose a citation manager

Content to export